



Office of Strategic Business Management
Revenue Maximization and Grants Coordination Division
Ryan White Title I Program
111 NW 1st Street • 22nd Floor
Miami, Florida 33128-1994
T 305-375-4742 • F 305-375-4454

miamidade.gov

September 19, 2006

Dear Ryan White Title I Service Provider:

Enclosed for your information and distribution is a **revised** Ryan White Title I Prescription Drug Formulary sorted in the order of drug classification, brand name, and generic name. This new version will also be disseminated in electronic PDF format to facilitate its use and dissemination to all interested parties. Please note, this new version will also be available on the Office of Strategic Business Management's Ryan White Title I Program website.

Effective August 14, 2006, at the recommendation of the Miami-Dade HIV/AIDS Partnership, the following medications have been added to the Formulary:

Drug Classification – Nucleoside Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors Combination

Generic

Efavirenz/Emtricitabine/Tenofovir*

Trade/Brand Name

Atripla

Drug Classification – Protease Inhibitors

Generic

Darunavir*

Trade/Brand Name

Prezista

* It is important to note that Title I will **not** reimburse for these medications prior to the drugs being available at the AIDS Drug Assistance Program's (ADAP) central pharmacy.

In addition to the change indicated above, the Miami-Dade HIV/AIDS Partnership in conjunction with the Ryan White Title I Program, has approved the deletion of the following prescription drug products from the Title I Prescription Drug Formulary. The Title I Program temporarily suspended coverage of these medications on March 1, 2003 in order to maximize the use of public and private resources available in the community for pharmaceutical services and conserve limited resources under the Ryan White Title I program for HIV/AIDS related medications. After careful consideration, the Partnership has decided not to reinstate the use of Title I funds to pay for the following medications listed below. This policy change is to be effective August 14, 2006.

Drug Classification – Anabolic Agents (Discontinued)

Generic

Oxandrolone

Oxymetholone


Trade/Brand Name

Oxandrin

Anadrol-50

The Ryan White Title I Prescription Drug Formulary is **revised** periodically by the Miami-Dade HIV/AIDS Partnership. It is imperative that all revisions to the Formulary be carefully reviewed and understood by direct service staff and recipients of the Title I-funded medications. Please notify program staff and clients immediately of these revisions. If further clarification is needed on these recent changes to the Formulary, please contact Theresa Wright, Contracts Officer, at (305) 375-4742.

Sincerely,



Theresa Fiaño

Program Director

Ryan White Title I Program

Enclosure

cc: Theresa Wright, Contracts Officer, OSBM
Carla Valle-Schwenk, Program Administrator, OSBM
Vivian Gonzalez-Cao, Accountant III, OSBM
Andrae Corrigan, President, ACMS, Inc. (local office)